GRAND FORKS, North Dakota, February 20, 2019 (GLOBE NEWSWIRE) – # 9 Labs Corp. (OTC: INLB) (# 9 Labs or the Company), a leading developer and manufacturer of innovative cannabis products and proprietary delivery platforms. announced today that the medical marijuana dispensary, Strive Life North Dakota, a partner of the company's business model and brand, has signed a letter of intent with Pure Dakota, LLC, a leading supplier and manufacturer of salable marijuana.
The deal is the first of its kind in the country and will ensure a steady supply of much-anticipated marijuana medicines as soon as Strive Life North Dakota opens its doors.
For more information, visit StriveWellnessofNorthDakota.com.
The operation of Strive Life in North Dakota follows the business model of Strive Life, which introduces the best medical marijuana practices in the United States and globally. The dispensary model provides thoughtful environments for a higher patient experience.
"We look forward to having Pure Dakota as one of our key suppliers," said Sara Gullickson, CEO of Item 9 Labs.
Strive Life North Dakota was approved in November 2018 for a registration certificate for a pharmacy, one of only eight state-awarded certificates. The surgery is expected to begin in April / May 2019 and will provide a diverse inventory of patient-focused products.
"We have absolute respect for Pure Dakota. Together, as trusted providers, we will promote patient wellbeing, "commented Jonathan O`Keefe, founder of Strive Life North Dakota.
Pure Dakota operates a 20,000-square-meter facility and houses 1,000 marijuana plants, the maximum under state law. It is one of two licensed manufacturers in North Dakota.
In addition to the Strive Life brand, Item 9 Labs is an industry leader in the development and manufacture of innovative marijuana products and proprietary delivery platforms. Item 9 Labs will operate as licensed pharmacies, manufacturing and manufacturing facilities in approved US markets by the end of 2019.
For more information, see Item9LabsCorp.com.
Information about Article 9 Labs Corp.:
Item 9 Labs Corp. (OTC: INLB) creates convenient cannabis health solutions for the modern consumer through the development of innovative products and proprietary delivery platforms. The company is focused on developing technology and products that manage high-quality medical marijuana through a novel intra-nasal delivery system for significant health benefits. The company is headquartered in Southern Arizona, where it owns and operates 50 acres, one of the largest properties in the US where the medical marijuana flower is grown. Point 9 has proven to be successful in providing consumers with high quality medicinal marijuana flowers and products that are targeted at organic, cost-effective body health solutions. By combining a high-quality medical device with the company's proprietary nasal mucosal delivery system, Item 9 plans to launch the industry's first commercial nasal delivery device, which will deliver specific cannabinoid dosages to meet the growing needs of the modern To cover today's cannabis users. For more information visit us online at www.Item9labscorp.com and www.Item9labs.com,
This news release contains forward-looking statements within the meaning of the Safe Harbor provisions of the Private Infringement Procedures Act 1995. These statements involve risks and uncertainties, including risks and repercussions of legal and administrative procedures as well as government regulation, particularly in a foreign country, future financial and operating results, competition, general economic conditions, planned transactions that are not legally binding obligations of the Company, and the ability to control and continue the growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those stated. Important factors that could cause actual results to differ materially from the forward-looking statements made in this press release include the introduction of new technology, market conditions and those contained in reports or documents that we occasionally file with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date of this Agreement or the occurrence of unexpected events.
Contact for investors:
Item 9 Labs Corp.